Bio‑Techne has secured exclusive commercial rights to a subset of Monod Bio’s NovoBody™ Duo molecules, a new class of AI‑designed bispecific binding proteins. The agreement, announced on November 18, 2025, gives Bio‑Techne the ability to license, develop, and sell these molecules worldwide, positioning the company to accelerate product development in high‑growth areas such as cell and gene therapy, spatial biology, and diagnostics.
Monod Bio, a Seattle‑based spin‑out from David Baker’s laboratory at the University of Washington, has built a platform that uses artificial intelligence to design novel protein binders. The NovoBody™ Duo molecules are engineered to bind two distinct targets simultaneously, offering compact size, tunable affinity, and rapid manufacturability compared with traditional antibodies. The partnership validates Monod’s technology and provides Bio‑Techne with a portfolio of next‑generation research tools and therapeutic candidates that can be customized quickly and cost‑effectively.
The deal fits squarely into Bio‑Techne’s broader AI‑driven protein strategy. By adding NovoBody™ Duo molecules to its recombinant protein lineup, the company can offer customers faster, cheaper, and more stable alternatives to conventional antibodies. This capability is expected to broaden Bio‑Techne’s market reach, support its expansion into cell‑therapy and regenerative‑medicine platforms, and create new revenue streams in research and clinical development. The partnership also strengthens Bio‑Techne’s competitive position in the life‑science tools market, where AI‑enabled innovation is becoming a key differentiator.
Financially, Bio‑Techne reported net sales of $1.2 billion for fiscal 2025 and employs roughly 3,100 people worldwide. In the fourth quarter of fiscal 2025, the company generated $317 million in revenue and reported an adjusted earnings per share of $0.53, beating analyst expectations of $0.50. While the terms of the licensing agreement were not disclosed, the addition of NovoBody™ Duo molecules is expected to contribute to future revenue and margin expansion as the company scales its AI‑engineered protein platform. The deal also aligns with Bio‑Techne’s recent earnings trend, where adjusted operating margins have remained stable despite a modest decline in the Diagnostics and Spatial Biology segment due to unfavorable product mix.
Management emphasized the strategic value of the partnership. Will Geist, President of the Protein Sciences segment, said the molecules “extend our portfolio with innovative AI‑powered designs and state‑of‑the‑art customization, stability, and performance, enabling customers to target complex biology with greater precision.” Alfredo Quijano Rubio, Chief Science Officer of Monod Bio, highlighted the molecules’ “compact, tunable, and rapidly adaptable” nature, while CEO Daniel Silva Manzano noted that the collaboration “validates our platform and accelerates the integration of Monod’s AI‑designed proteins into mainstream life sciences.”
The licensing agreement reflects a broader industry trend toward AI‑driven protein design. As companies seek faster, cheaper, and more versatile binders, partnerships like this one are becoming a key growth engine. While no immediate market reaction has been reported, the deal signals Bio‑Techne’s continued commitment to AI innovation and positions it to capture new opportunities in the evolving life‑science landscape.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.